OncoMatch/Clinical Trials/NCT07211659
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Is NCT07211659 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies THEO-260 for ovarian cancer.
Treatment: THEO-260 — The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will also aim to establish if THEO-260 is able to treat ovarian cancer. The main questions it aims to answer are: * What medical problems do participants have when taking THEO-260? * At what dose is THEO-260 both safe but also shows signs of being able to treat ovarian cancer? The clinical trial follows a dose escalation/ finding design where we will aim to establish a Recommended Phase 2 Dose (RP2D). Participants will: * Be administered 6 doses of THEO-260 via an intraperitoneal (IP) route of administration over the course of 2 weeks. * They will then visit the clinic at regular intervals for check-ups and tests to monitor safety and THEO-260 ability to treat ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Grade: high grade
Confirmed histological diagnosis of advanced high grade serous or endometrioid cancer of the fallopian tube, primary peritoneum or ovary
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Platinum-resistant or refractory disease: platinum-resistance is defined as radiological progression within 6 months of last cycle of platinum treatment; platinum refractory disease is defined as radiological progression during the 3 months following the first dose with platinum treatment.
Cannot have received: group B adenovirus
Prior treatment with a group B adenovirus.
Cannot have received: radiation therapy
Radiation therapy within 4 weeks of first dose of THEO-260.
Cannot have received: investigational product
Prior anti-cancer treatment or receipt of investigational product within 28 days or 5 half-lives, prior to first dose of THEO-260 or patients with unresolved serious toxic side-effects of prior chemotherapy or radiotherapy.
Lab requirements
Blood counts
Adequate haematological and organ function (parameters apply).
Kidney function
Adequate haematological and organ function (parameters apply).
Liver function
Adequate haematological and organ function (parameters apply).
Adequate haematological and organ function (parameters apply).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify